HIV/AIDS Treatment

Viracept 625 mg receives positive opinion in Europe

Published in AIDS Weekly, February 16th, 2004

Roche announced that a positive opinion has been granted by the European Committee on Proprietary Medicinal Products (CPMP) recommending marketing authorization for a new 625-mg formulation of Viracept (nelfinavir), an HIV drug.

The final marketing approval is expected to follow later this year.

The new formulation will reduce Viracept's pill count from 10 tablets per day to 4 tablets per day. Moreover, Viracept 625 mg is reported to offer a marked reduction in the occurrence of diarrhea and was clearly preferred by patients in a recent study.

"The new Viracept 625-mg formulation with less pills and less diarrhea is good news for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2004-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry